343321-96-0

343321-96-0 structure

Name: GW590735
Chemical Name: GW 590735
CAS Number: 343321-96-0
Molecular Formula: C₂₃H₂₁F₃N₂O₄S
Molecular Weight: 478.48
Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
Create Date: 2021-12-22 10:52:30
Modify Date: 2024-01-12 18:12:49
GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia[1].

Name	GW 590735
Synonyms	MFCD12912339 2-Methyl-2-(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}carbonyl)amino]methyl}phenoxy)propanoic acid 2-methyl-2-(4-(((4-methyl-2-(4-trifluoromethylphenyl)-thiazol-5-ylcarbonyl)amino)methyl)phenoxy)propionic acid Propanoic acid, 2-methyl-2-[4-[[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]carbonyl]amino]methyl]phenoxy]- GW 590735 GW-590735 QKY617BBX5

Description	GW 590735 is a potent and selective PPARα agonist. GW 590735 showsEC50=4 nM on PPARα and at least 500-fold selectivity versus PPARδ and PPARγ. GW 590735 can be used for the research of dyslipidemia[1].
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR Research Areas >> Metabolic Disease
In Vivo	GW 590735 (0.5-5 mg/kg; orally twice a day for 5 days) is able to lower LDLc and triglycerides (TG) and increase HDL cholesterol in the Apo-A-I-transgenic mouse model (male C57BL/6 mice transgenic for human ApoA-I)[1]. GW 590735 (intravenous administration; 2.7 mg/kg; rat) treatment shows Cl, Vd, T1/2, and F% are 5 mL/min/kg, 1 L/kg, 2.4 hours and 47%, respectively[1]. GW 590735 (intravenous administration; 2 mg/kg; dog) treatment shows Cl, Vd, T1/2, and F% are 13 mL/min/kg, 2.8 L/kg, 2.6 hours and 85%, respectively[1].
References	[1]. Sierra ML, et al. Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J Med Chem. 2007;50(4):685-695.